Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Clonal relationships between lobular carcinoma in situ and other breast malignancies.

Begg CB, Ostrovnaya I, Carniello JV, Sakr RA, Giri D, Towers R, Schizas M, De Brot M, Andrade VP, Mauguen A, Seshan VE, King TA.

Breast Cancer Res. 2016 Jun 23;18(1):66. doi: 10.1186/s13058-016-0727-z.

2.

Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.

King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, Oskar S, Guerini-Rocco E, Boafo C, Gooch JC, De Brot M, Reis-Filho JS, Morrogh M, Andrade VP, Sakr RA, Morrow M.

J Clin Oncol. 2015 Nov 20;33(33):3945-52. doi: 10.1200/JCO.2015.61.4743. Epub 2015 Sep 14.

PMID:
26371145
3.

Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases.

Cutuli B, De Lafontan B, Kirova Y, Auvray H, Tallet A, Avigdor S, Brunaud C, Delva C.

Radiat Oncol. 2015 May 6;10:110. doi: 10.1186/s13014-015-0379-7.

4.

Genetic predisposition to in situ and invasive lobular carcinoma of the breast.

Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, Fletcher O, Pinder S, Hanby A, Kohut K, Gorman P, Caneppele M, Peto J, Dos Santos Silva I, Johnson N, Swann R, Dwek M, Perkins KA, Gillett C, Houlston R, Ross G, De Ieso P, Southey MC, Hopper JL, Provenzano E, Apicella C, Wesseling J, Cornelissen S, Keeman R, Fasching PA, Jud SM, Ekici AB, Beckmann MW, Kerin MJ, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Guénel P, Truong T, Laurent-Puig P, Kerbrat P, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Perez JI, Menéndez P, Benitez J, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Meindl A, Lichtner P, Schmutzler RK, Lochmann M, Brauch H, Fischer HP, Ko YD; GENICA Network, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova NV, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Chenevix-Trench G, Investigators K, Lambrechts D, Weltens C, Van Limbergen E, Hatse S, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Radice P, Peterlongo P, Bonanni B, Volorio S, Giles GG, Severi G, Baglietto L, McLean CA, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Kristensen V, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Devillee P, Tollenaar RA, Seynaeve CM, Kriege M, Figueroa J, Chanock SJ, Sherman ME, Hooning MJ, Hollestelle A, van den Ouweland AM, van Deurzen CH, Li J, Czene K, Humphreys K, Cox A, Cross SS, Reed MW, Shah M, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Couch FJ, Hallberg E, González-Neira A, Pita G, Alonso MR, Tessier DC, Vincent D, Bacot F, Bolla MK, Wang Q, Dennis J, Michailidou K, Dunning AM, Hall P, Easton D, Pharoah P, Schmidt MK, Tomlinson I, Garcia-Closas M.

PLoS Genet. 2014 Apr 17;10(4):e1004285. doi: 10.1371/journal.pgen.1004285. eCollection 2014 Apr.

5.

Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting.

Middleton LP, Sneige N, Coyne R, Shen Y, Dong W, Dempsey P, Bevers TB.

Cancer Med. 2014 Jun;3(3):492-9. doi: 10.1002/cam4.223. Epub 2014 Mar 18.

6.

Germline CDH1 mutations in bilateral lobular carcinoma in situ.

Petridis C, Shinomiya I, Kohut K, Gorman P, Caneppele M, Shah V, Troy M, Pinder SE, Hanby A, Tomlinson I, Trembath RC, Roylance R, Simpson MA, Sawyer EJ.

Br J Cancer. 2014 Feb 18;110(4):1053-7. doi: 10.1038/bjc.2013.792. Epub 2013 Dec 24.

7.

Is there a role for routine screening MRI in women with LCIS?

King TA, Muhsen S, Patil S, Koslow S, Oskar S, Park A, Morrogh M, Sakr RA, Morrow M.

Breast Cancer Res Treat. 2013 Nov;142(2):445-53. doi: 10.1007/s10549-013-2725-5. Epub 2013 Oct 19.

8.

Breast cancer preoperative staging: does contrast-enhanced magnetic resonance mammography modify surgery?

Perono Biacchiardi C, Brizzi D, Genta F, Zanon E, Camanni M, Deltetto F.

Int J Breast Cancer. 2011;2011:757234. doi: 10.4061/2011/757234. Epub 2011 Jul 3.

9.

Breast cancer medications and vision: effects of treatments for early-stage disease.

Eisner A, Luoh SW.

Curr Eye Res. 2011 Oct;36(10):867-85. doi: 10.3109/02713683.2011.594202. Epub 2011 Aug 5. Review.

10.
11.

Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.

Hall MJ, Reid JE, Wenstrup RJ.

Cancer Prev Res (Phila). 2010 Dec;3(12):1579-85. doi: 10.1158/1940-6207.CAPR-09-0218.

12.

Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy.

Ciocca RM, Li T, Freedman GM, Morrow M.

Ann Surg Oncol. 2008 Aug;15(8):2263-71. doi: 10.1245/s10434-008-9960-8. Epub 2008 May 28.

13.

Genomics and premalignant breast lesions: clues to the development and progression of lobular breast cancer.

Mastracci TL, Boulos FI, Andrulis IL, Lam WL.

Breast Cancer Res. 2007;9(6):215. Review.

14.

Non-operative breast pathology: lobular neoplasia.

Reis-Filho JS, Pinder SE.

J Clin Pathol. 2007 Dec;60(12):1321-7. Epub 2006 Dec 20. Review.

15.
Items per page

Supplemental Content

Write to the Help Desk